Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Alex K, Bryant"'
Autor:
Alex K. Bryant, Rafael Zamora‐Resendiz, Xin Dai, Destinee Morrow, Yuewei Lin, Kassidy M. Jungles, James M. Rae, Akshay Tate, Ashley N. Pearson, Ralph Jiang, Lars Fritsche, Theodore S. Lawrence, Weiping Zou, Matthew Schipper, Nithya Ramnath, Shinjae Yoo, Silvia Crivelli, Michael D. Green
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Purpose Real world evidence is crucial to understanding the diffusion of new oncologic therapies, monitoring cancer outcomes, and detecting unexpected toxicities. In practice, real world evidence is challenging to collect rapidly and compreh
Externí odkaz:
https://doaj.org/article/24564ba419ab4b8aac5c0b927356a621
Autor:
Kyung Min Lee, Alex K. Bryant, Patrick Alba, Tori Anglin, Brian Robison, Brent S. Rose, Julie A. Lynch
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3727-3730 (2023)
Abstract The COVID‐19 pandemic disrupted prostate‐specific antigen (PSA) screening and prostate biopsy procedures. We sought to determine whether delayed screening and diagnostic workup of prostate cancer (PCa) was associated with increased subse
Externí odkaz:
https://doaj.org/article/f6433a9d3ab04c36bfa47130122a3a51
Autor:
Alex K. Bryant, Tyler J. Nelson, Rana R. McKay, A. Karim Kader, J. Kellogg Parsons, John P. Einck, Christopher J. Kane, Ajay P. Sandhu, Arno J. Mundt, James D. Murphy, Brent S. Rose
Publikováno v:
BJUI Compass, Vol 3, Iss 3, Pp 243-250 (2022)
Abstract Objective To analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer (PCa) treated with radiation therapy. Subjects and methods We identified 12 784 patients with intermediate‐ or high‐risk localized PCa
Externí odkaz:
https://doaj.org/article/3a39c19fc659410aa09ae9d48b9b56a7
Autor:
Nikhil V. Kotha, Daniel R. Cherry, Alex K. Bryant, Vinit Nalawade, Tyler F. Stewart, Brent S. Rose
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 28, Iss , Pp 133-140 (2021)
Background and purpose: Neutrophil-lymphocyte ratio (NLR) has been associated with overall survival (OS) in non-small cell lung cancer (NSCLC). We aimed to assess the utility of NLR as a predictor of lung cancer-specific survival (LCS) and identify a
Externí odkaz:
https://doaj.org/article/beb1594f5fc844d5828e0717d763f0d3
Autor:
Kathleen M Akgün, Keith Sigel, Kei-Hoi Cheung, Farah Kidwai-Khan, Alex K Bryant, Cynthia Brandt, Amy Justice, Kristina Crothers
Publikováno v:
PLoS ONE, Vol 15, Iss 1, p e0227730 (2020)
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is associated with poor quality of life, hospitalization and mortality. COPD phenotype includes using pulmonary function tests to determine airflow obstruction from the forced expiratory volume
Externí odkaz:
https://doaj.org/article/41a375cc3aa8484b85ad6a73ecce24a7
Autor:
Alex K. Bryant, Kamya Sankar, Lili Zhao, Garth W. Strohbehn, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, Michael D. Green
Publikováno v:
European Journal of Cancer. 171:55-63
One year of adjuvant durvalumab following concurrent chemoradiotherapy significantly improves progression-free survival (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the optimal length of adj
Autor:
Steven G. Allen, Aleksandar F. Dragovic, Huiying (Maggie) Yin, Alex K. Bryant, Peter A. Paximadis, Martha M. Matuszak, Matthew J. Schipper, Robert T. Dess, James A. Hayman, Michael M. Dominello, Larry L. Kestin, Benjamin Movsas, Shruti Jolly, Derek P. Bergsma
Publikováno v:
Practical Radiation Oncology.
Our primary analysis focused on radiation-treated cancer survivors alive at least 5 years from diagnosis. Supplemental Table S1 demonstrates the primary analysis where we vary the required length of survivorship from 1 to 10 years, focusing on the ni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fd6aafbc8a7f3386826307ab21f7ab
https://doi.org/10.1158/1055-9965.22438521
https://doi.org/10.1158/1055-9965.22438521
Autor:
Loren K. Mell, Jingjing Zou, Andrew B. Sharabi, Alex K. Bryant, Paul J. Riviere, Kaveh Zakeri, Lucas K. Vitzthum, Caroline A. Thompson, Tyler J. Nelson, Casey W. Williamson
Purpose:Cancer treatments can paradoxically appear to reduce the risk of noncancer mortality in observational studies, due to residual confounding. Here we introduce a method, Bias Reduction through Analysis of Competing Events (BRACE), to reduce bia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30cf92803f0c887b84b3a4da8d998b10
https://doi.org/10.1158/1078-0432.c.6531107.v1
https://doi.org/10.1158/1078-0432.c.6531107.v1
Autor:
Loren K. Mell, Jingjing Zou, Andrew B. Sharabi, Alex K. Bryant, Paul J. Riviere, Kaveh Zakeri, Lucas K. Vitzthum, Caroline A. Thompson, Tyler J. Nelson, Casey W. Williamson
Supplementary Data from Bias Reduction through Analysis of Competing Events (BRACE) Correction to Address Cancer Treatment Selection Bias in Observational Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf8803f53a5bf00a12a800196985ae0f
https://doi.org/10.1158/1078-0432.22483307.v1
https://doi.org/10.1158/1078-0432.22483307.v1